(Press-News.org) TUCSON, Ariz. August 13, 2024– Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today that Kenneth Keiler, Ph.D., Professor of Molecular Biosciences at the University of Texas at Austin, has been awarded a research grant for his innovative project titled “Inhibitors of the Gram-negative Cell Envelope Stress Response as Anti-Infectives and Antibiotics.” This funding will support Dr. Keiler’s original approach to addressing the critical issue of antibiotic-resistant Gram-negative bacterial infections.
Despite the availability of numerous approved medicines for Gram-negative infections, the rapid rise in antibiotic resistance far outpaces the development of new therapeutic options. Such resistance is particularly severe in hospital environments, where multi-drug-resistant strains pose significant treatment challenges.
Dr. Keiler’s research focuses on developing inhibitors that target the stress response systems of Gram-negative bacteria. His research could lead to new treatments for life-threatening infections caused by Gram-negative pathogens, offering a promising solution to an urgent medical need.
Maaike Everts, Ph.D., Executive Director of TRxA, commented, “We are delighted to support Dr. Keiler’s inventive work. His approach to target the stress response systems of Gram-negative bacteria represents a significant leap forward in our fight against antibiotic resistance. This research has the potential to develop new treatments that are not subject to the current resistance mechanisms, which is crucial for improving patient outcomes.”
Dr. Keiler expressed his gratitude for the grant, stating, “I am honored to receive this support from TRxA and am eager to advance our research. Addressing the challenge of antibiotic resistance in Gram-negative bacteria is imperative, and we believe that by targeting their stress response systems, we can develop effective new treatments that will significantly impact patient care.”
TRxA’s support for Dr. Keiler’s research highlights C-Path’s dedication to advancing innovative solutions that accelerate the development of therapies for people with unmet medical needs. For more information about C-Path and TRxA, visit c-path.org/trxa.
About Critical Path Institute
Critical Path Institute (C-Path) is an independent, nonprofit established in 2005 as a public-private partnership, in response to the FDA’s Critical Path Initiative. C-Path’s mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path’s global headquarters is located in Tucson, Arizona and C-Path’s Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org.
About TRxA
Critical Path Institute’s Translational Therapeutics Accelerator (TRxA) is a global drug accelerator focused on supporting academic scientists in advancing novel therapeutics from university-based labs to drug development pipelines of pharmaceutical companies and, ultimately, the clinic. As a non-profit neutral convener of patient groups, academia, pharmaceutical companies and regulatory agencies, C-Path brings a breadth of scientific and drug development planning not available in other accelerator programs. TRxA is uniquely situated to leverage the expertise available through C-Path’s >20 disease-based consortia, as well as regulatory expertise and project management, to empower academic investigators to succeed in bringing safe and effective treatments to patients. For more information, visit c-path.org/trxa or email trxa@c-path.org.
Contacts:
Roxan Triolo Olivas
C-Path
520.954.1634
rolivas@c-path.org
Kissy Black
C-Path
615.310.1894
kblack@c-path.org
END
C-Path’s TRxA announces $250,000 grant for drug development project on antibiotic-resistant gram-negative bacteria
2024-08-13
ELSE PRESS RELEASES FROM THIS DATE:
Crnic Institute clinical trial shows JAK inhibitor improves multiple autoimmune conditions in patients with Down syndrome
2024-08-13
A new study published in eLIFE by researchers from the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz Medical Campus reports the initial results of a first-in-kind clinical trial testing the safety and efficacy of a JAK inhibitor to decrease the burden of autoimmune conditions in people with Down syndrome. The clinical trial, which is funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, is part of a portfolio of new clinical trials supported by the National Institutes of Health INCLUDE Project.
Drawing upon their 2016 discovery that the interferon ...
New study looks at drug exposures of COVID-19 therapy for pregnant people
2024-08-13
A new study provides important insights into the pharmacokinetics and safety of intravenous remdesivir in treating the SARS-CoV-2 coronavirus in pregnant women.
Remdesivir is an antiviral medication and is used to treat certain patients with COVID-19 who are either hospitalized or have mild-to-moderate symptoms in the outpatient setting and are at high risk of severe disease.
The study, published in the Journal of Infectious Diseases, is the first pharmacokinetic study to be published on a COVID-19 therapy in pregnant women. Pharmacokinetic studies ...
Business crucial to addressing toxic pollution and protecting human health
2024-08-13
By Josh Stowe
Toxic pollution is the single largest cause of death and poor health, killing up to 9 million people each year — about 100 times more than war and terrorism combined. Business produces the bulk of this deadly pollution, but can also play a critical role in addressing it and mitigating its effects, according to new research by University of Notre Dame expert Richard (Drew) Marcantonio.
Marcantonio, whose study was recently published in Business Horizons, is assistant professor of environment, peace and global affairs in Notre Dame’s Keough ...
SwRI-led team finds evidence of hydration on Psyche
2024-08-13
SAN ANTONIO — August 13, 2024 —Using data from NASA’s James Webb Space Telescope, a Southwest Research Institute-led team has confirmed hydroxyl molecules on the surface of the metallic asteroid Psyche. The presence of hydrated minerals suggests a complex history for Psyche, important context for the NASA spacecraft en route to this interesting asteroid orbiting the Sun between Mars and Jupiter.
At about 140 miles in diameter, Psyche is one of the most massive objects in the main asteroid belt. Previous observations indicate that Psyche is a dense, largely metallic object that could be a leftover core from a planet that experienced ...
$18M ARPA-H award supports Rice-led research on tumor analysis system for breast, head and neck cancer
2024-08-13
A Rice University-led multi-institutional research collaboration has won an award of up to $18 million over five years from the Advanced Research Projects Agency for Health (ARPA-H) to develop and validate a new system for improving tumor removal accuracy for two types of cancer: breast, and head and neck cancer.
Called AccessPath, the novel, affordable, slide-free cancer pathology system will help surgeons know whether they have completely removed tumors during surgery by enabling rapid, automatic tumor margin classification of resected tumors. AccessPath is one of several projects funded through the ARPA-H Precision Surgical Interventions program announced today ...
Common equine painkiller disrupts assisted reproduction technique efficiency in mares, Texas A&M research finds
2024-08-13
By Courtney Price, Texas A&M University School of Veterinary Medicine and Biomedical Sciences
Researchers at the Texas A&M School of Veterinary Medicine & Biomedical Sciences (VMBS) have discovered that phenylbutazone, a non-steroidal anti-inflammatory drug (NSAID) commonly prescribed in horses, can affect the ability of a mare’s egg cells — called “oocytes” — to become viable embryos, which is a crucial step in assisted reproduction in horses.
This discovery, recently published in the journal Theriogenology, is significant because of the time and money that horse owners ...
Coherence entropy unlocks new insights into light-field behavior
2024-08-13
Light technology is at the heart of many cutting-edge innovations, from high-speed internet to advanced medical imaging. However, transmitting light through challenging environments, such as turbulent atmospheres or deformed optical systems, has always posed a significant hurdle. These complexities can distort and disrupt the light field, making it difficult to achieve clear and reliable results. Scientists have long sought ways to overcome these limitations, and a new breakthrough may hold the key to advance practical applications.
As reported in Advanced Photonics, researchers at Soochow ...
Mizzou scientists achieve more than 98% efficiency removing nanoplastics from water
2024-08-13
COLUMBIA, Mo. — University of Missouri scientists are battling against an emerging enemy of human health: nanoplastics. Much smaller in size than the diameter of an average human hair, nanoplastics are invisible to the naked eye.
Linked to cardiovascular and respiratory diseases in people, nanoplastics continue to build up, largely unnoticed, in the world’s bodies of water. The challenge remains to develop a cost-effective solution to get rid of nanoplastics while leaving clean water behind.
That’s where Mizzou comes in. Recently, researchers at the university created a new liquid-based solution that eliminates more than 98% of these microscopic ...
Electric scooter–related injuries are becoming more frequent and costly
2024-08-13
August 13, 2024 — The introduction of publicly shared electric scooters (“e-scooters”) in Denver, Colorado has resulted in a steady increase in injuries and hospital admissions, according to research led by Alexander Lauder, MD, an orthopedic surgeon at Denver Health Medical Center. The findings are presented in Clinical Orthopaedics and Related Research® (CORR®), a publication of The Association of Bone and Joint Surgeons®. The journal is published in the Lippincott portfolio by Wolters Kluwer.
"International ...
Children born prematurely fall into three groups
2024-08-13
About thirteen million babies each year are born prematurely, with preterm birth linked to increases in risk for attention-deficit/hyperactivity disorder (ADHD), problems with social development, and lower grades.
A problem with past analyses of prematurity, however, is that they do not capture the variety seen in children born pre-term, including some with outcomes better than the average results for full- term children. Pre-term means birth before 37 weeks of gestation, with full term being 40 weeks.
The tendency to lump preterm babies into one group hinders efforts to tailor care for any one child, researchers say. Now a new study, published online August 13 ...